Literature DB >> 25337050

Prostate-specific Antigen Velocity Risk Count to Discern Significant From Indolent Prostate Cancer.

Dara Lundon1, Stacy Loeb2.   

Abstract

Entities:  

Year:  2014        PMID： 25337050      PMCID： PMC4191640     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  12 in total

1.  Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

Authors:  Stacy Loeb; E Jeffrey Metter; Donghui Kan; Kimberly A Roehl; William J Catalona
Journal:  BJU Int       Date:  2012-02-01       Impact factor: 5.588

2.  Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.

Authors:  H Ballentine Carter; Anna Kettermann; Luigi Ferrucci; Patricia Landis; E Jeffrey Metter
Journal:  Urology       Date:  2007-10       Impact factor: 2.649

3.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.

Authors:  H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; E James Wright; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter
Journal:  J Natl Cancer Inst       Date:  2006-11-01       Impact factor: 13.506

4.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

5.  Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).

Authors:  Tineke Wolters; Monique J Roobol; Chris H Bangma; Fritz H Schröder
Journal:  Eur Urol       Date:  2008-03-11       Impact factor: 20.096

6.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

7.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

Authors:  H B Carter; J D Pearson; E J Metter; L J Brant; D W Chan; R Andres; J L Fozard; P C Walsh
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

8.  Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.

Authors:  Hiten D Patel; Zhaoyong Feng; Patricia Landis; Bruce J Trock; Jonathan I Epstein; H Ballentine Carter
Journal:  J Urol       Date:  2013-09-20       Impact factor: 7.450

Review 9.  Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.

Authors:  Andrew J Vickers; Caroline Savage; M Frank O'Brien; Hans Lilja
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

10.  Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection.

Authors:  D S Smith; W J Catalona
Journal:  J Urol       Date:  1994-10       Impact factor: 7.450
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.